All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering Committee About Us Newsletter Contact

Visit:

You're logged in! Click here any time to manage your account or log out.

Steering Committee About Us Newsletter Contact

Brought to you by

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.

Types Therapeutics Congresses Trials Expert Opinions Educational Resources DRUG UPDATES

Multiple Myeloma Types

2021-03-29T13:39:47.000Z

What are the key differences between bispecific antibodies and CAR T cells?

By Georgia Scurfield, Alice Hyde, Maria Kasimati

Featured

Hermann Einsele

Mar 29, 2021

Bookmark this article

Video series

1

2:41

What is there to know about the EBMT GoCART coalition?

Sofie Terwel

3:02

What are the key differences between bispecific antibodies and CAR T cells?

Hermann Einsele

3

5:25

Where are we on anti-BCMA CAR T-cell therapies for MM?

María-Victoria Mateos

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Hermann Einsele, Julius-Maximilians-Universität Würzburg, Würzburg, DE. We asked, What are the key differences between bispecific antibodies and CAR T cells?

In this video, Einsele provides an overview of the main differences in the mode of operation, efficacy, and side effects of these two classes of therapeutic agent for patients with multiple myeloma.

More about...

CAR therapy EBMT EBMT 2021 T-cell engagers

Video series

1

2:41

What is there to know about the EBMT GoCART coalition?

Sofie Terwel

3:02

What are the key differences between bispecific antibodies and CAR T cells?

Hermann Einsele

3

5:25

Where are we on anti-BCMA CAR T-cell therapies for MM?

María-Victoria Mateos

Your opinion matters

At what point would you adopt a treatment regimen for multiple myeloma that received FDA approval based on MRD-negative CR as a primary endpoint?

1 vote - 21 days left ...

Subscribe to get the best content related to multiple myeloma delivered to your inbox